Business
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patientsPluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calcul
About this update from Pluri Inc.
[{"type":"image","alt":"Pluri Inc.","displaySize":"","headline":null,"caption":"Pluri Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":120,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/d5a4051630c54382ed0eee086a38698c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tW4todUQDjndMreKHMwkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d5a4051630c54382ed0eee086a38698c","width":120,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancers","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Pluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Pluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 billion in 2025","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"In addition to MAIT cells, Pluri’s platform also supports the expansion of Tumor Infiltrating Lymphocytes (TILs), further broadening the scope of potential immune cell therapies in cancer immunotherapy and attracting attention in the growing TILs-focused research space","length":269,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":802,"olType":false},{"type":"text","content":"HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a patent covering the Company’s immune cell expansion technologies. This patent specifically includes MAIT cells, a unique subset of T cells that are crucial in helping the body fight infection and repair tissue. Additionally, Pluri was issued a patent in Israel, which mirrors previously granted US patent. Pluri’s total intellectual property (“IP”) estate now includes over 2...